Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Differential Modulation of Agonist Potency and Receptor Coupling by Mutations of Ser388Tyr and Thr389Pro at the Junction of Transmembrane Domain VI and the Third Extracellular Loop of Human M1 Muscarinic Acetylcholine Receptors

Xi-Ping Huang, Frederick E. Williams, Steven M. Peseckis and William S. Messer Jr.
Molecular Pharmacology October 1999, 56 (4) 775-783;
Xi-Ping Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederick E. Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Peseckis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William S. Messer Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Transmembrane domain VI of muscarinic acetylcholine receptors plays an important role in ligand binding and receptor function. A human M1 (HM1) mutant receptor, HM1(S388Y, T389P), displayed significantly enhanced agonist potency, binding affinity, and G protein coupling. The mutations are located at the top of transmembrane domain VI and about two helical turns above Tyr381 and Asn382, which are important for ligand binding and receptor function. To determine the functional role of individual mutations of Ser388Tyr and Thr389Pro, we created stable A9 L cell lines expressing HM1(S388Y) or HM1(T389P) receptors. In phosphatidylinositol hydrolysis assays, muscarinic agonists showed greater potency at the HM1(S388Y) and HM1(S388Y, T389P) mutants compared with the wild-type and HM1(T389P) receptors. Acetylcholine demonstrated 105-fold higher potency at HM1(S388Y) receptors than at HM1(T389P) receptors. Choline (30 μM, the concentration found in Dulbecco’s modified Eagle’s medium) exhibited 90% stimulation at HM1(S388Y) receptors but was inactive at HM1(T389P) receptors. In ligand binding experiments, mutation of Ser388Tyr resulted in significantly increased agonist binding affinity. In contrast, mutation of Thr389Pro did not change agonist binding affinity but rendered multiple agonist binding sites, and the high-affinity binding was sensitive to GTP analogs. These results demonstrate that the Ser388Tyr mutation is responsible for enhanced agonist potency and binding affinity, whereas the Thr389Pro mutation alters G protein interactions. The data suggest that Ser388 and Thr389 are potential targets for modulation of agonist binding and G protein coupling.

Footnotes

  • Send reprint requests to: William S. Messer, Jr., Ph.D., Department of Medicinal and Biological Chemistry, College of Pharmacy, The University of Toledo, 2801 W. Bancroft St., Toledo, OH 43606-3390. E-mail:wmesser{at}uoft02.utoledo.edu.

  • This work was supported by Grants NS01493, NS31173, and NS35127. Portions of this work have appeared in abstract and poster form and were presented at the 8th International Symposium on Subtypes of Muscarinic Receptors, Danvers, MA, August 1998, and at the 28th annual meeting of the Society for Neuroscience, Los Angeles, CA, November 1998. This work is part of the Ph.D. dissertation of X.-P.H., Department of Medicinal and Biological Chemistry, College of Pharmacy, The University of Toledo.

  • Abbreviations:
    ACh
    acetylcholine
    mAChR
    muscarinic acetylcholine receptor
    CCh
    carbachol
    Gpp(NH)p
    guanosine-5′-(β,γ-imido)triphosphate
    PI
    phosphatidylinositol
    HM1
    human muscarinic acetylcholine receptor subtype 1
    NMS
    N-methylscopolamine
    Oxo
    oxotremorine
    Oxo-M
    oxotremorine-M
    PLC
    phospholipase C
    (R)-QNB
    (R)-3-quinuclidinyl benzilate
    Ne3
    N-terminal region of the third extracellular loop
    TM
    transmembrane domain
    R-SAT
    receptor selection and amplification technology
    WT
    wild-type
    • Received January 26, 1999.
    • Accepted June 21, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 56 (4)
Molecular Pharmacology
Vol. 56, Issue 4
1 Oct 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Differential Modulation of Agonist Potency and Receptor Coupling by Mutations of Ser388Tyr and Thr389Pro at the Junction of Transmembrane Domain VI and the Third Extracellular Loop of Human M1 Muscarinic Acetylcholine Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Differential Modulation of Agonist Potency and Receptor Coupling by Mutations of Ser388Tyr and Thr389Pro at the Junction of Transmembrane Domain VI and the Third Extracellular Loop of Human M1 Muscarinic Acetylcholine Receptors

Xi-Ping Huang, Frederick E. Williams, Steven M. Peseckis and William S. Messer
Molecular Pharmacology October 1, 1999, 56 (4) 775-783;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Differential Modulation of Agonist Potency and Receptor Coupling by Mutations of Ser388Tyr and Thr389Pro at the Junction of Transmembrane Domain VI and the Third Extracellular Loop of Human M1 Muscarinic Acetylcholine Receptors

Xi-Ping Huang, Frederick E. Williams, Steven M. Peseckis and William S. Messer
Molecular Pharmacology October 1, 1999, 56 (4) 775-783;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • EIPA, HMA and SMN2 gene regulation
  • Clc-2 has minor role in intestinal Cl- secretion
  • Resveratrol acts as an NR4A1 antagonist in lung cancer.
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics